Integral Diagnostics Ltd · ASX:IDX
Integral Diagnostics — Shareholder Meeting (November 2022)
23 slides from Integral Diagnostics's shareholder meeting presentation, Nov 4, 2022
Slide 1: AGM Address and Presentation by the Chair and Managing Director/CEO
T +61 3 5339 0704 E info@idxgroup.com.au Suite 9.02, Level 9, 45 William Street Melbourne Vic 3000 www.integraldiagnostics.com.au For personal use only AGM Address and Presentation by the Chair and Managing Director/CEO 4 November 2022, Melbourne Attached are copies of the address and presentati
Slide 2: Chair Address
Integral Diagnostics Limited 2022 Annual General Meeting For personal use only Chair Address Slide 1 – Chair Address I am proud to be a part of a company whose purpose is to deliver the best possible outcomes for our patients by providing diagnostic imaging services, in order to diagnose and treat i
Slide 3: Chair Address: FY23 outlook and governance highlights
Benowa and Burleigh Heads on the Gold Coast and O’Connor in Perth, which opened in October 2021, April 2022 and June 2022 respectively. For personal use only IDX secured targeted acquisitions in existing geographies to expand the scope and depth of service locations to patients and broaden our refer
Slide 4: ESG and closing remarks
The Board has continued the advancement of its environmental, social and governance (ESG) For personal use only responsibilities and again produced a dedicated ESG Report in accordance with the Global Reporting Initiative (GRI) Standards: Core Option. Our Board approved ESG Strategy aligns with the
Slide 5: Managing Director and CEO Presentation
Integral Diagnostics Limited 2022 Annual General Meeting For personal use only Managing Director and CEO Presentation Slide 4 - Managing Director and CEO Presentation Thank you, Helen and good morning, everyone. It’s good to see you all, in the room and online. I am also proud to be a part of a comp
Slide 6: IDX Operates in Key Geographic Markets
Slide 7 - IDX Operates in Key Geographic Markets For personal use only This table reflects the extent of our practices across Australia and New Zealand, including our most recent acquisitions. IDX now has 91 sites, 36 MRI’s and 6 PET-CT’s, soon to be 7 as we install a new PET-CT in Auckland next mon
Slide 7: Regulatory commentary and PSMA PET CT Scans
In NZ, the Accident Compensation Commission (ACC) has not applied indexation to radiology pricing in FY23. Private health funds, accounting for about 25% of our NZ payer base, have provided reasonable indexation. For personal use only Slide 10 - PSMA PET CT Scans for Diagnosis of Metastatic Prostate
Slide 8: Referral practices and Medicare utilisation
Referring to some recent Australian press articles where reports of alleged over-utilisation of services in the broader Medicare system have been called out. For personal use only It is important to highlight that radiologists depend on referrals from GPs and other medical specialists and do not gen
Slide 9: IDX Focus in FY23
Slide 13 - IDX Focus in FY23 Our FY23 focus is on organic growth, integrating recent strategic acquisitions and executing For personal use only selected greenfield and brownfield opportunities. We are investing in digital PET-CT services in Ballarat, Auckland and the Gold Coast, and investing in MRI
Slide 10: Chair Address
For personal use only CHAIR ADDRESS Helen Kurincic
Slide 11: Financial Performance
FINANCIAL PERFORMANCE FY22 For personal use only 20.0% 46.2% 2.8% 26.1% 53.5% 43.1% decline in decline in increase in decline Net debt / decline in decline in operating operating operating in free cash EBITDA (pre- statutory NPAT operating NPAT EBITDA EPS revenue flow AASB16) $14.6m $21.7m $74.8m 10
Slide 12: Governance Highlights
GOVERNANCE HIGHLIGHTS For personal use only Board • Governance model for our specialised medical business includes two Radiologist Executive Directors • New independent Non-Executive Director Andrew Fay commenced in July 2022 • Mr Fay is a highly experienced ASX Company Director with over 30 years e
Slide 13: Managing Director & CEO Presentation
For personal use only MANAGING DIRECTOR & CEO PRESENTATION Dr Ian Kadish
Slide 14: Delivering on Our Values in FY22
DELIVERING ON OUR VALUES IN FY22 For personal use only • Served 800,000 patients • 245 reporting radiologists • 1,868 employees • Operating NPAT declined by • Managed workflows, personnel – 162 employees 43.1% to $21.7m in a COVID-19 and systems to continue to • Performed >2 million exams • Develope
Slide 15: Strong Historical Performance Track Record Impacted by COVID-19 in FY22
STRONG HISTORICAL PERFORMANCE TRACK RECORD IMPACTED BY COVID-19 IN FY22 For personal use only Operating EBITDA ($m) Operating Revenue ($m) 358.7 93.5 348.8 75.7 74.8 274.1 231.0 53.0 188.0 38.1 FY18 FY19 FY20 FY21 FY22 FY18* FY19* FY20 FY21 FY22 Operating Diluted Earnings Per Share EBITDA Operating
Slide 16: IDX Operates in Key Geographic Markets
IDX OPERATES IN KEY GEOGRAPHIC MARKETS Western Victoria Queensland New Zealand Australia For personal use only 5 5 Total IDX Geographic Queensland Western Victoria Victoria & NSW Queensland Queensland New Zealand New Zealand Market & NSW Australia Ballarat, Albury, Geelong, Wodonga, Sunshine Coast,
Slide 17: DI Industry COVID-19 Impact: Australia
DI INDUSTRY COVID-19 IMPACT: AUSTRALIA For personal use only Radiology growth since 1994 (with CAGR)* • FY22 was the most challenging year the industry has experienced. Australian industry revenue declined by 2.8% • Much of the decline was driven by the decrease in GP and specialist in-clinic consul
Slide 18: FY23 Regulatory Environment
FY23 REGULATORY ENVIRONMENT For personal use only Australia: New Zealand: Medicare Changes • The Accident Compensation Commission (ACC) has not applied • MRI Licenses indexation to radiology pricing in FY23. Private health funds have provided indexation - On 1 November 2022 the MRI license regime wi
Slide 19: PSMA PET-CT Scans for Diagnosis of Metastatic Prostate Cancer
PSMA PET-CT SCANS FOR DIAGNOSIS OF METASTATIC PROSTATE CANCER For personal use only • Prostate cancer is the most common cancer in Australian men, >19,000 cases/year • The five-year survival from prostate cancer has improved from 59% to 95% • Prostate Specific Membrane Antigen (PSMA) Positron Emissi
Slide 20: FY23 External Environment
FY23 EXTERNAL ENVIRONMENT For personal use only • The role that DI plays in early detection and prevention of disease • Immigration caps in Australia and New Zealand recently lifted. increasingly recognised: Doctor shortages are single biggest challenge in improving healthcare services in Australia
Slide 21: Strategy and YTD Trading Update
STRATEGY AND YTD TRADING UPDATE 1 Grow existing business and margin 2 Strategic acquisitions For personal use only Strategy Accelerate use of Drive organic growth - teleradiology, digital Drivers of Nurture and develop including selective price and AI to improve the Drive our environmental, Focus on
Slide 22: IDX Focus in FY23
IDX FOCUS IN FY23 FY23 focus is on For personal use only organic growth, integrating recent strategic acquisitions and select brownfield and greenfield opportunities AGM 2022 13
Slide 23: For personal use only
For personal use only
Integral Diagnostics — Shareholder Meeting (November 2022) on 6ix